BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Humacyte readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Humacyte's drugs run\, from Clini
 calTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05908084-1249@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Human Acellular Vessel (Humacyte): Phase 3 readout est. (NCT0590808
 4)
DESCRIPTION:Human Acellular Vessel (Humacyte)\, phase 3.\nStudy: To Compare
  the Efficacy and Safety of the ATEV With AVF in Female Patients With End-
 Stage Renal Disease Requiring Hemodialysis\nEstimated primary completion: 
 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/human-acel
 lular-vessel-humacyte#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05908084
URL:https://assetmemo.bio/drug/human-acellular-vessel-humacyte#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07762313-1249@assetmemo.bio
DTSTAMP:20261121T005826Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Human Acellular Vessel (Humacyte): Phase 3 readout est. (NCT0776231
 3)
DESCRIPTION:Human Acellular Vessel (Humacyte)\, phase 3\, Vascular Trauma.\
 nStudy: An Open-label Study to Assess the Safety and Efficacy of SYMVESS®
  as a Vascular Conduit in Adolescents With Extremity Arterial Injury.\nEst
 imated primary completion: December 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/human-acellular-vessel-humacyte#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07762313
URL:https://assetmemo.bio/drug/human-acellular-vessel-humacyte#upcoming-eve
 nts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
